- Home
- REVB
as 11-15-2024 4:00pm EST
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.1M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.70 - $25.26 | Next Earning Date: | 11-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Revelation Biosciences Inc. News
REVB Breaking Stock News: Dive into REVB Ticker-Specific Updates for Smart Investing
Business Wire
6 days ago
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
Zacks Small Cap Research
7 days ago
REVB Results Set Stage for Future Growth
Business Wire
9 days ago
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
Business Wire
2 months ago
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10
MT Newswires
3 months ago
Top Premarket Decliners
Business Wire
3 months ago
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
Zacks Small Cap Research
3 months ago
REVB: Bolsters Cash Amid Positive Trial Results
Business Wire
3 months ago
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024
Compare REVB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REVB Revelation Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.